BPP treatment reduced the disposition and accumulation of ECM by enhancing ECM degradation via up‐regulating the expression levels of MMPs and down‐regulating the expression levels of TIMPs, resulting in the reversion of the balance between degradation and disposition of ECM towards degradation, and thus, improving renal fibrosis. The gene discussed is SRPX2; the disease is renal fibrosis.